Dishman Carbogen's Q1 2024 Financial Report Shows Negative Performance and 'Strong Sell' Rating

Dishman Carbogen, a smallcap pharmaceutical company, recently announced its financial results for the quarter ending March 2024. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.

According to the financial report, Dishman Carbogen has seen a negative performance in the quarter, with a score of -7. However, this is an improvement from the previous quarter's score of -17.

One of the major factors contributing to the negative performance is the company's Profit After Tax (PAT), which has fallen by 166.3% year on year, standing at Rs -66.83 crore. The near-term trend for PAT is also negative.

Another concerning aspect is the company's interest expenses, which have grown by 22.37% over the preceding nine months period, standing at Rs 91.52 crore. This indicates an increase in borrowings for the company.

Furthermore, the company's Profit Before Tax less Other Income (PBT) has also seen a decline of 9.32% year on year, standing at Rs -53.27 crore. The near-term trend for PBT is also negative.

Overall, Dishman Carbogen's financial performance for the quarter ending March 2024 has not been favorable. Investors should take note of these factors before making any investment decisions. This news is based on the company's financial report and the stock rating given by MarketsMOJO.